During the after-market session on Tuesday, Sight Sciences, Inc. (NASDAQ: SGHT) witnessed a substantial surge in its stock value, indicating a sustained momentum in its market performance. SGHT shares experienced a notable increase of 8.67% after hours on the US stock market, reaching a price point of $4.51.
Throughout the regular trading hours, SGHT displayed stability, with a modest yet significant rise of 0.73%, concluding the session at $4.15. This upward trajectory in SGHT’s stock price is largely attributed to a strategic advancement within the company’s operations.
The Ergo-Series of the OMNI Surgical System, which Sight Sciences just introduced to the European market, caused quite a stir. This cutting-edge device is intended to let individuals with open-angle glaucoma undergo minimally invasive, implant-free glaucoma operations.
Since its March 2023 premiere in the US, the Ergo-Series has become a popular choice among OMNI surgeons due to its improved ergonomics and specially designed cannula tip that allows for comfortable and accurate access to Schlemm’s canal.
Building upon the positive reception from US surgeons, Sight Sciences has successfully obtained the CE Mark under the new EU Medical Device Regulation, thereby paving the way for the marketing of this upgraded version of its OMNI technology across Europe.
The company is poised to showcase the improved handle ergonomics, simplified viscoelastic preparation, and new cannula tip design at the prestigious European Society of Cataract and Refractive Surgeons (“ESCRS”) Winter meeting in Frankfurt later this month.
The remarkable ergonomic enhancements of the OMNI Ergo-Series hold promise for enhancing user-friendliness, potentially motivating surgeons to intervene earlier in appropriate cases. This proactive approach can play a crucial role in delaying disease progression and preserving vision, while also potentially reducing the medication burden for glaucoma patients.
The redesigned Ergo-Series not only makes the device more intuitive to handle and operate but also ensures gentle and precise access to Schlemm’s canal, accompanied by improved tactile feedback, which instills confidence in surgeons throughout the procedure.
These advancements further expand the accessibility of OMNI for surgeons treating various stages of open-angle glaucoma, marking a significant stride in the field of ophthalmic surgery.
